(redirected from Bone marrow suppression)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Wikipedia.


(computer science)
Removal or deletion usually of insignificant digits in a number, especially zero suppression.
Optional function in either on-line or off-line printing devices that permits them to ignore certain characters or groups of characters which may be transmitted through them.
Elimination of any component of an emission, as a particular frequency or group of frequencies in an audio-frequency of a radio-frequency signal.



in genetics, a phenomenon that prevents the appearance of a character resulting from mutation and that causes partial or complete restoration of the normal phenotype.

Intragenic suppression is caused by a second (suppressor) mutation in the same gene in which the first (direct) mutation occurred. Intergenic suppression is caused by a second mutation in other genes that are located at a considerable distance from the suppressed gene. In intragenic suppression, a protein coded by a given gene can reacquire functional activity, although its original structure, in contrast to true reverse mutation, or reversion, is not restored. In intergenic suppression, the normal phenotype may be restored in some cases owing to mutations that permit other means of metabolism which do not require the functioning of the given gene. In other cases, the normal phenotype may be restored as a result of mutations that alter the process by which the genetic information of the mutant gene is realized.

The phenomenon of suppression, first discovered in 1920 by the American geneticist A. H. Sturtevant, is used to study the genetic code and other aspects of molecular genetics.


Stent, G. Molekuliarnaia genetika. Moscow, 1974. Chapter 6. (Translated from English.)


References in periodicals archive ?
Over 600 patients to date have received romidepsin in clinical trials with the most common adverse effects including fatigue, gastrointestinal disturbances and generally mild to moderate bone marrow suppression.
Four percent (4%) of patients in the Xofigo arm and 2% in the placebo arm permanently discontinued therapy due to bone marrow suppression.
However, the physiopathology of the bone marrow suppression in this disease is still unclear.
Acute lymphocytic leukemia developed within 3 weeks after a fulminant case of varicella complicated by pneumococcal sepsis and severe bone marrow suppression in a child treated with filgrastim (human granulocyte colony-stimulating factor).
The most common toxicities were mild to moderate and gastrointestinal or renal related, with no reports of central nervous system or bladder toxicities and no significant bone marrow suppression or alopecia.
Furthermore, single agent and combination studies exhibited a favorable safety profile with no evidence of bone marrow suppression.
With the exception of Fas and sFas-L results, other changes could better be explained by bone marrow suppression with varicella infection because of their similarity.
This clinical variant represents severe bone marrow suppression and secondary cryptococcosis, which is a rare complication of methotrexate treatment and is frequently fatal.

Full browser ?